Posted by Michael Wonder on 01 Feb 2022
Reata Pharmaceuticals initiates rolling submission of new drug application with U.S. FDA for omaveloxolone for the treatment of patients with Friedreich’s ataxia
31 January 2022 - Plans to complete submission by the end of the first quarter of 2022.
Reata Pharmaceuticals today announced that the company has initiated a rolling submission of a new drug application to the U.S. FDA for omaveloxolone for the treatment of patients with Friedreich’s ataxia.
